GLP-1 coverage for weight loss tied to much more use

Clinical takeaway: Whether a patient can get a GLP-1 for weight loss increasingly depends on their plan's coverage of the obesity-only indication, a gap that widened sharply through 2024. Stay aware of coverage changes and additional indications insurers might cover, which could expand access for your patients.

Employers deciding whether to cover GLP-1s for weight loss have been flying blind on what it costs them. The clinical benefit is largely accepted, but the budget impact of the obesity-only indication had not been measured in real plans. A new cross-sectional analysis of employer claims fills that gap, tracking utilization and cost in plans that cover weight loss against those that cover GLP-1s only for diabetes and heart disease. For prescribers, the upshot is that a patient's access now turns heavily on a coverage decision employers are still making with thin evidence.

Plans that covered the weight-loss indication and those that did not started 2021 nearly even, at 128.2 versus 121.5 GLP-1 days supplied per 1000 enrollees, a 5.5% gap. By December 2024 both had climbed steeply, but covering plans pulled far ahead, rising to 1260.0 days per 1000 enrollees from a much smaller base of growth in non-covering plans, which reached 766.8. That widened the gap to 64.3%.

The cost of that divergence is modest per member but rising. In 2024, covering GLP-1s for weight loss added an estimated $9.23 to $16.21 for every member per month, the range reflecting the drop in net drug price from about $12,000 a year in 2021 to $6,830 in 2025. Whether lower medical spending offsets that total cost is unquantified.

This analysis is the first to put real-world employer numbers on a coverage question that had been argued mostly in projections. Roughly 6.3 million patients across 5,787 plans and 1,756 employers were included, and only about 15% of plans covered the weight-loss indication throughout the period.

The cross-sectional study drew on 2021 to 2024 claims from employer-sponsored UnitedHealthcare plans, all of which covered GLP-1s for diabetes and cardiovascular disease. Researchers compared plans that also covered the weight-loss indication against those that did not, tracking days supplied of dual-labeled GLP-1 drugs per 1000 enrollees. To be conservative, a fill counted as weight-loss use only when a patient had an obesity or overweight diagnosis and no prior diabetes or cardiovascular disease. The two plan populations were demographically similar.

Because the claims capture only plan-covered fills, they miss GLP-1s bought through self-pay or compounding, a large channel during the shortage years. Real access in non-covering plans was likely higher than these numbers show, and the true coverage gap somewhat narrower. As branded supply stabilizes and compounded versions face tighter limits, more demand may shift back to covered claims, which could widen the measured gap further.

Source: Shahzad M, et al. JAMA Health Forum. 2026 Jun 26. GLP-1 prescriptions for weight loss by differences in insurance plan coverage